Q1 Earnings Forecast for Immunocore Issued By HC Wainwright

Key Points

• HC Wainwright raised its Q1 2027 EPS estimate for Immunocore to $0.07 from $0.05 and reiterated a Buy rating with a $100 price target.
• Other analysts were also broadly positive: Zacks Research upgraded the stock from strong sell to strong-buy, while the overall consensus remains a Moderate Buy with an average target of $57.75.
• Immunocore recently reported $0.25 EPS for the quarter, beating expectations, though revenue of $106.68 million came in below forecasts despite being up 13.6% year over year.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) - Equities researchers at HC Wainwright raised their Q1 2027 earnings estimates for Immunocore in a research note issued on Thursday, May 7th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.07 for the quarter, up from their prior forecast of $0.05. HC Wainwright currently has a "Buy" rating and a $100.00 price target on the stock. The consensus estimate for Immunocore's current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Immunocore's Q2 2027 earnings at $0.17 EPS, Q3 2027 earnings at $0.28 EPS, Q4 2027 earnings at $0.38 EPS, FY2027 earnings at $0.90 EPS, FY2028 earnings at $4.16 EPS, FY2029 earnings at $7.36 EPS and FY2030 earnings at $10.55 EPS.

Several other brokerages have also issued reports on IMCR. Needham & Company LLC lifted their price target on shares of Immunocore from $71.00 to $75.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Weiss Ratings restated a "sell (e+)" rating on shares of Immunocore in a research note on Tuesday, April 21st. Zacks Research upgraded shares of Immunocore from a "strong sell" rating to a "strong-buy" rating in a research note on Thursday. Mizuho set a $38.00 price objective on shares of Immunocore in a research note on Thursday, February 19th. Finally, Wall Street Zen upgraded shares of Immunocore from a "hold" rating to a "buy" rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $57.75.

Immunocore Price Performance

Shares of IMCR stock opened at $29.58 on Monday. The company has a current ratio of 4.18, a quick ratio of 4.15 and a debt-to-equity ratio of 1.00. Immunocore has a 1 year low of $27.44 and a 1 year high of $40.71. The firm's fifty day moving average price is $30.87 and its two-hundred day moving average price is $33.32. The firm has a market capitalization of $1.50 billion, a P/E ratio of -53.78 and a beta of 0.74.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.51. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The business had revenue of $106.68 million for the quarter, compared to analyst estimates of $145.20 million. During the same period last year, the business posted $0.10 earnings per share. The firm's quarterly revenue was up 13.6% on a year-over-year basis.

Insider Buying and Selling at Immunocore

In other Immunocore news, insider Leger Tina Amber St sold 1,000 shares of the business's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $32,350.00. Following the completion of the sale, the insider owned 1,119 shares of the company's stock, valued at $36,199.65. The trade was a 47.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David M. Berman sold 5,965 shares of the business's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the completion of the sale, the insider directly owned 5,859 shares of the company's stock, valued at $189,538.65. This represents a 50.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 19,137 shares of company stock valued at $619,082 in the last quarter. Company insiders own 10.40% of the company's stock.

Hedge Funds Weigh In On Immunocore

Several hedge funds and other institutional investors have recently made changes to their positions in IMCR. Royal Bank of Canada increased its position in Immunocore by 45.1% during the 1st quarter. Royal Bank of Canada now owns 44,011 shares of the company's stock worth $1,306,000 after purchasing an additional 13,689 shares in the last quarter. Geode Capital Management LLC increased its position in Immunocore by 40.1% during the 2nd quarter. Geode Capital Management LLC now owns 52,001 shares of the company's stock worth $1,632,000 after purchasing an additional 14,877 shares in the last quarter. Marshall Wace LLP increased its position in Immunocore by 425.8% during the 2nd quarter. Marshall Wace LLP now owns 146,610 shares of the company's stock worth $4,601,000 after purchasing an additional 118,728 shares in the last quarter. Sei Investments Co. acquired a new position in Immunocore during the 2nd quarter worth approximately $983,000. Finally, Cubist Systematic Strategies LLC increased its position in Immunocore by 108.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 142,757 shares of the company's stock valued at $4,480,000 after acquiring an additional 74,128 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore News Summary

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: HC Wainwright raised multiple 2027–2028 earnings estimates for Immunocore and maintained a Buy rating with a $100 price target, signaling confidence in the company’s longer-term growth outlook.
• Positive Sentiment: Zacks Research upgraded Immunocore from strong sell to strong-buy, adding to the bullish tone around the stock.
• Neutral Sentiment: Recent commentary also highlighted Immunocore’s valuation after strong Q1 2026 results and new KIMMTRAK survival data, which may be reinforcing investor interest. A Look At Immunocore (IMCR) Valuation After Strong Q1 2026 Results And New KIMMTRAK Survival Data
• Negative Sentiment: Not all forecast changes were positive: HC Wainwright trimmed its FY2029 and FY2030 EPS estimates slightly, which tempers the overall optimism.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body's own T‐cell response to treat cancer and infectious diseases. The company's proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company's most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.